HC Wainwright Reiterates “Buy” Rating for IN8bio (NASDAQ:INAB)

HC Wainwright reaffirmed their buy rating on shares of IN8bio (NASDAQ:INAB) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

IN8bio Stock Performance

IN8bio stock opened at $0.31 on Tuesday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. The firm has a market cap of $22.47 million, a P/E ratio of -0.41 and a beta of -0.07. IN8bio has a 1-year low of $0.22 and a 1-year high of $2.48. The firm has a 50-day moving average of $0.30 and a 200-day moving average of $0.64.

IN8bio (NASDAQ:INAB) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Sell-side analysts expect that IN8bio will post -0.56 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp lifted its stake in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 851,280 shares of the company’s stock after buying an additional 251,600 shares during the quarter. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.